Cellectar Biosciences (CLRB) announced that the first patient has been enrolled in the Phase 1b trial of CLR 121125 for the potential treatment of triple negative breast cancer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLRB:
- Cellectar Biosciences upgraded to Buy from Hold at Maxim
- Cellectar Biosciences Charts Risky Path to Approvals
- Cellectar Biosciences price target lowered to $14 from $18 at Roth Capital
- Cellectar Biosciences reports FY25 EPS ($8.35) vs ($41.89) last year
- CLRB Upcoming Earnings Report: What to Expect?